Last Updated on October 6, 2024 by The Health Master
USFDA Approval
In a significant development, Granules India Limited, a prominent player in the pharmaceutical industry, announced that it has received USFDA approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) concerning the blood pressure-lowering medication Losartan Potassium and Hydrochlorothiazide tablets.
These tablets come in strengths of 50 mg/12.5 mg, 100 mg/12.5 mg, and 100 mg/25 mg.
Details of the Approval
Granules’ latest achievement signifies a major stride in their efforts to provide accessible healthcare solutions.
The newly approved medication, a generic equivalent of Organon LLC’s Hyzaar, not only effectively lowers blood pressure but also diminishes the risk of stroke in patients dealing with hypertension and left ventricular hypertrophy.
Market Potential and Estimates
As of July 2023, estimations place the annual market value for this drug at a substantial US$73 million.
This projection underscores the critical role this medication is poised to play in addressing the healthcare needs of a wide demographic.
Granules’ Expanding Portfolio
This recent USFDA approval catapults Granules‘ total ANDA approvals to an impressive count of 60 from the USFDA.
Among these, 58 are final approvals, while the remaining two are tentative approvals.
This robust portfolio attests to Granules’ unwavering commitment to delivering high-quality, affordable pharmaceuticals to the market.
In-Depth Insight into Losartan Potassium and Hydrochlorothiazide Tablets
- Mechanism of Action:
- The medication combines the effectiveness of Losartan Potassium and Hydrochlorothiazide to combat hypertension.
- Losartan potassium acts as an angiotensin II receptor antagonist, relaxing blood vessels and lowering blood pressure.
- Hydrochlorothiazide is a diuretic that eliminates excess salt and water from the body, further aiding in blood pressure regulation.
- Clinical Significance:
- The drug not only addresses high blood pressure but also offers added protection by reducing the risk of strokes in patients grappling with hypertension and left ventricular hypertrophy.
- Market Impact:
- The approval of Granules’ generic version provides an affordable alternative for patients, enhancing accessibility to this critical medication.
Future Prospects
Granules India Limited is poised for a promising future, fortified by this recent milestone.
The company’s commitment to excellence and its expanding portfolio of FDA-approved medications position it as a key player in the global pharmaceutical landscape.
Insights into the USFDA Drug Approval Process:
1. Regulatory Affairs Consulting:
- Essential for navigating the complex landscape of USFDA approvals.
- Ensures adherence to stringent regulatory guidelines.
2. USFDA Drug Approval Process:
- A meticulous process involving rigorous evaluation of safety and efficacy.
- Demands comprehensive documentation and compliance with USFDA standards.
3. Generic Drug Approval Pathway:
- An economical alternative to brand-name drugs, requiring a robust Abbreviated New Drug Application (ANDA).
- Necessitates a thorough demonstration of bioequivalence.
4. USFDA Expedited Programs:
- Designed to accelerate the approval process for drugs addressing unmet medical needs.
- Includes Fast Track Designation, Breakthrough Therapy Designation, Priority Review Process, and Accelerated Approval Process.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA approval granted for Blood Smear Application
USFDA approval granted for Icosapent Ethyl capsules
USFDA Approval granted for Dolutegravir Tablets
USFDA approval granted for Norelgestromin and Ethinyl Estradiol Transdermal System
Breakthrough Pediatric HIV Treatment Receives Tentative USFDA Approval
PLI Scheme: Boosting Pharmaceutical and Medical Device Manufacturing
CDSCO approval granted for Palivizumab preventive therapy
NMC Regulations: Stringent Measures for Medical Colleges
Recent Amendments in NIPER to appoint Director
USFDA issues Form 483 with one observation to Aurobindo: Andhra Pradesh
USFDA issues warning letter to Fresenius Kabi: Read detail
Amendment in D&C Act: Decriminalizing Offences for Trust-Based Governance
USFDA gives positive Inspection Report to Lupin: Nagpur
Drug recall: Ibrexafungerp tablets recalled due to cross contamination
USFDA’s New Inspection Approach for India’s Pharmaceutical Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon: